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Incorporation of organic functionalities within porous materials is a very elegant manner to
control the administration of therapeutic drugs. Delayed drug-release profile originates from
weak and reversible interactions (e.g., electrostatic, hydrophobic–hydrophobic and H-bonding
interaction) between the modified carrier and the drug molecule. Two new silsesquioxane
PMO precursors were synthesized in a quick and facile Schotten-Baumann reaction of
(3-aminopropyltriethoxy)silane and (N-methyl-3-aminopropyltrimethoxy)-silane with malonylchloride,
respectively. Based on these bis(3-(triethoxysilyl)propyl)malonamide (MA) and N,N-dimethyl-N,N-
bis(3-(triethoxysilyl)propyl)malonamide (mMA) precursors, an extensive range of 2D hexagonal
PMOs with high functional loading was obtained by the co-condensation with tetraethyl orthosili-
cate (TEOS) in a typical PMO synthesis (acidic medium, P123, KCl). The materials showed good
ordering up to 20 mol% of functional loading, a large surface area (up to 550 m2/g) and wide pores
(∼7 nm). The malonamide-type PMOs are capable to adsorb large amounts of ibuprofen (130 mg/g)
as a hydrophobic model drug. Release experiments are performed in a phosphate buffer solution
at pH 7.4 and show a controlled desorption of Ibuprofen over 24 hours; a largely expanded times
pan compared to mesoporous silicas. Moreover, we are able to tune the release profile by varying
the content of organic bridges in the PMO pores.
Keywords:
1. INTRODUCTION
Since the discovery of Periodic Mesoporous Organosilicas
(PMOs) in 19991 as an evolution from M41S and SBA15
ordered silicas, these advanced hybrid materials have been
the centre of profound research.2 Generally, PMOs are
synthesized by the hydrolysis and subsequent condensa-
tion of a silsesquioxane precursor, typically (R’O)3Si–
R–Si(OR’)3, around a micelle template. The organic R
group allows the incorporation of a functional bridge
into the siloxane framework of PMO materials. In this
way, the advantages of mesoporous silicas (MPS), such
as an ordered pore structure with a tunable pore size and
a high internal surface area, are combined with a non-
leachable built-in functionality. Furthermore, the organic
bridge also allows introducing certain hydrophobicity into
the framework. This greatly increases the hydrothermal
and mechanical stability of PMOs,3 as the siloxane bridge
∗Authors to whom correspondence should be addressed.
is less susceptible to hydrolysis compared to pure silica
materials.
In recent years a plethora of different functional
bridges have been reported, delivering multi-purpose
carriers for very diverse applications in for example
catalysis,4 adsorption,5 chromatography,6 low-k insulators7
and photoluminescence.8 Moreover, the chemical stability
and non-toxic nature of PMO materials have lately led to
a largely emerging field in biomedical applications such as
supports for enzymatic bio-catalysis9 and protein enrich-
ment and refolding.10
Controlled administration of drug molecules however
remains a challenge, regarding such systems need to con-
trol the rate and period of drug delivery to maintain ther-
apeutic drug levels during treatment, instead of a typical
spike or burst release in classical therapy. Biodegradable
polymers are often used as a host material for controlled
drug release (CDR).11 The mechanical mixing of the drug
with the polymer matrix is required to load the drug onto
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the polymer. However, this often leads to inhomogeneous
distribution of the therapeutics, which in its turn gives
mediocre results in terms of controlled release.
Porous materials (i.e., MPS,12 hydroxyapatite,13 metal-
organic frameworks14 are shown to be very promising
candidates as controlled drug delivery systems due to
their large internal surface area and arranged pore sys-
tems, which allows a high and homogeneous uptake of
both easily and poorly water-soluble therapeutic drugs.
Numerous model drugs, such as ibuprofen, itraconazole,
naproxen, aspirin, captopril, etc., have been screened
in MPS.15 The biocompatibility of silica-based materi-
als makes them especially attractive alternatives as for
example regulated delivery of an anti-inflammatory drug
(ibuprofen) can be combined with the possibility to bone
tissue regeneration.13(b)15 Furthermore, MPS have been
shown to enhance oral bioavailability of poorly water-
soluble drugs.16
Tailoring the pore size through the use of different sur-
factants influences the release profile of ibuprofen (IBU)
from MCM-41 type silicas.17 However, a slower release
rate is accompanied with a decrease of total IBU amount
released as IBU molecules are physically entrapped inside
the small pores. Research on SBA-15 type materials
showed total release of all IBU adsorbed.18 The use of
these large-pored materials as CDR system is however dis-
putable as the total IBU dose is released within 2–3 h.
The Vallet-Regi research group observed
delayed IBU-release from MCM-41 grafted with
3-aminopropyl(triethoxy)silane and attributed this to
altered host-drug interactions on the surface of the silica
matrix.19 Poor hydrolytic stability of the grafted Si–O–Si
bond renders such an approach inapplicable in the human
body as undesired leaching of the functionality might
occur. Research on ethyl-bridged PMOs illustrated the
effects of hydrophobicity on the release profile of a very
hydrophobic drug such as tetracycline.20 Also, CDR was
demonstrated on carboxylic acid functionalized PMOs.21
In both cases, however, a significant drop in total amount
of drug released is observed as drug molecules are too
strongly adsorbed to the carrier.
Recently, Moorthy et al., created amphoteric bis-silane
precursors to obtain stimuli-responsive (pH) functionalities
inside the pore walls of a PMO.22 Amphoteric ury-
lene and amidoxime moieties were suggested to influ-
ence the release behavior of loaded drug molecules
via weak and reversible interactions such as electro-
static, hydrophobic–hydrophobic and H-bonding interac-
tions, while only slightly affecting the amount of drugs
released. Also, this pH dependent interaction implies that
no intricate pore-capping molecules or ‘gatekeepers’ must
be employed to avoid premature drug release.
Amide-resonance is very interesting for CDR as
this effect provides both amphoteric as well as nor-
mal amide character. Hence, all of the latter inter-
actions might occur in a reversible way. This may
drastically influence the release profile of IBU, as
a model drug, and ensures a high release of all
adsorbed drug molecules. Therefore, this contribution
proposes to synthesize new tailor-made bis(3-(tri-
ethoxysilyl)propyl)malonamide (MA) and N ,N -dimethyl-
N ,N -bis(3-(triethoxysilyl)propyl)malonamide (mMA)
precursors which are subsequently condensed around a
large co-block polymer template (P123) to form PMO
materials with large pores to avoid irreversible entrapment
of IBU. Both MA and mMA functionalities are possi-
ble drug interaction sites. The nature of the occurring
interaction is assessed through a comparison of both
materials as for the methylated, tertiary amide func-
tionality of an mMA-PMO the N–H group, capable of
H-bonding, is exchanged for a N-Me group with increased
hydrophobicity. The (m)MA PMO materials are evaluated
as CDR-matrices for IBU in a phosphate buffer solution
(PBS) at pH 7.4 and body temperature. To investigate
the tunability of the release profile, PMOs with a varying
functional loading are synthesized.
2. EXPERIMENTAL SECTION
2.1. Materials
(3-aminopropyl)triethoxysilane (APTES, 98%) and (N-
methyl-3-aminopropyl)trimethoxysilane (mAPTMS) were
purchased from ABCR/Gelest. Malonylchloride (97%),
tetraethylorthosilicate (TEOS, 98%), Pluronic P123
(EO20PO70EO20, Mn = 5800) and triethylamine (>99%)
were obtained form Sigma-Aldrich. Ibuprofen was
acquired from TCI Europe and anhydrous diethylether
(Rotidry, >99.5%), HCl (37%) and hexane (>95%) from
Carl Roth. All reagents and solvents were used as received
without further purification.
2.2. Synthesis of Novel Malonamide-Type Precursors
To a solution of APTES (16.11 ml; 68 mmol) and
triethylamine (9.60 ml; 68 mmol) in 150 ml of dry
diethylether under inert atmosphere at 0 C, a solu-
tion of malonylchloride (5 g; 34 mmol) in 100 ml
dry diethylether was added dropwise over 30 min while
heavily stirring. This water-free Schotten-Baumann reac-
tion (Fig. 1) was selected to avoid hydrolysis of the
silsesquioxane species in the reaction. After 15 min, stir-
ring was switched off and the reaction mixture was left
to stand overnight. After filtration of a white precipi-
tate, diethyl ether was evaporated under reduced pres-
sure resulting in bis(3-(triethoxysilyl)propyl)malonamide
(1) as a red viscous oil. N ,N -dimethyl-N ,N -bis(3-
(trimethoxysilyl)propyl)malonamide (2) is obtained as a
slightly viscous orange oil via an analogous reaction of
mAPTMS (14.02 ml; 68 mmol) and malonylchloride (5 g;
34 mmol).
1: 1H NMR (CDCl3:  = 067 (t, 4H, SiCH2,
1.21 (t, 18H, OCH2CH3, 1.70 (quint, 4H, SiCH2CH2,
3.12 (s, 2H, OCCH2CO), 3.25 (t, 4H, NHCH2, 3.83
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Fig. 1. Synthesis of bis(3-(triethoxysilyl)propyl)malonamide (1), N ,N -dimethyl-N ,N -bis(3-(trimethoxysilyl)propyl)malonamide (2) and the respective
PMOs. MA and mMA PMOs are synthesized with×mol% of 1 and 2 respectively.
(q, 12H, OCH2;
13C NMR (CDCl3:  = 98 (SiCH2,
19.3 (OCH2CH3, 22.8 (SiCH2CH2, 42.1 (NHCH2, 42.5
(OCCH2CO), 58.7 (OCH2, 166 (C O).
2: 1H NMR (CDCl3:  = 063 (t, 4H, SiCH2, 1.65
(quint, 4H, SiCH2CH2, 2.91 (s, 6H, NCH3, 3.02 (t, 4H,
NCH2, 3.50 (s, 2H, OCCH2CO), 3.60 (s, 18H, OCH3
13C
NMR (CDCl3:  = 97 (SiCH2, 21.4 (SiCH2CH2, 35.8
(NCH3, 50.2 (OCH3, 50.3 (OCCH2CO), 52.6 (NCH2,
167 (C O).
2.3. Preparation of MA- and mMA-PMOs
Malonamide (MA) and N-methyl malonamide (mMA)
PMOs were synthesized in a typical hydrothermal pro-
cedure with a following molar ratio, P123:H2O:HCl:KCl:
1(2):TEOS—0.172:1876:60.9:49.3:x:10-x. P123, as a
structure directing agent was dissolved in the aqueous
solution of HCl and KCl. To this solution, a mixture with
varying amounts of PMO-precursor and TEOS was added.
Stirring was continued for 24 h at 40 C, followed by an
ageing step of 24 h at 95 C. In the course of the stirring
step an orange solid was formed, which was eventually
filtered off and thoroughly washed with 3× 20 ml H2O
en 3× 20 ml acetone. The P123 template was removed
via a Soxhlet extraction in acetone for 5 h, after which
the products were vacuum dried at 120 C. All samples
were named based on the precursor (MA, mMA) and its
initial molar percentage (x) relative to the total amount of
Si-sources.
2.4. Drug Loading Procedure and In-Vitro
CDR Experiments
In a procedure adapted from Song et al.,18 a stock solution
of 1 g/L IBU in hexane was prepared to perform adsorp-
tion experiments. Routinely, 50 mg of (m)MAx-PMO was
added to 50 ml of the IBU/hexane solution in a closed ves-
sel. This was shaken for 24 h in a temperature controlled
environment at 25 C, suspending all PMO particles. The
IBU-loaded materials were filtered off, swiftly washed
with 10 ml hexane and vacuum dried at room temperature.
A UV-VIS spectrometer (Shimadzu UV-1800 Spectropho-
tometer, 272 nm) was used to determine the amount of
IBU loaded on the solids, by change of the IBU concentra-
tion in the hexane solution before and after the adsorption
experiment. All experiments were at least performed in
threefold.
CDR experiments were conducted in-vitro in a PBS
(pH 7.4, 37 C) to mimic conditions of human flu-
ids. Approximately 30 mg of IBU-(m)MAx samples
were inserted in a membrane dialysis bag (Mw cut-off:
12.4 kDa) where upon they were suspended in 250 ml of
PBS. Gentle stirring was applied to reduce external dif-
fusion effects. A release profile was determined through
UV-VIS spectroscopy of 3 ml aliquots at set times.
2.5. Characterisation
NMR spectra (1H, 13C) of precursor 1 and 2, dissolved in
CDCl3, were recorded on a Bruker 300 MHz AVANCE
spectrometer. Chemical shifts ( are expressed in ppm
relative to a tetramethylsilane standard. X-Ray Powder
Diffraction (XRPD) pattern of the PMO materials were
recorded on a Thermo Scientific ARL X’TRA X-ray
diffractometer using Cu K radiation of 40 kV and 30 mA.
A Micromeretics Tristar 3000 was used for N2-sorption
experiments at 77 K to obtain the internal surface area
(SBET and pore size distribution (PSBJH making use of the
BET and BJH theory respectively. Prior to measurement,
all samples were vacuum dried at 120 C to evacuate all
adsorbed water. Diffuse Reflectance Infrared Spectroscopy
(DRIFTS) was performed using a Thermo Nicolett 6700
FT-IR spectrometer equipped with a Greasby-Specac dif-
fuse reflectance cell, modified to measure samples at
120 C under vacuum. For CHNS analysis, a Thermo
Flash 2000 elemental analyser was used with V2O5 as cat-
alyst. Thermogravitational Analysis (TGA) was performed
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on a Netzsch STA 449 F3 Jupiter with a heating rate
of 10 C/min and an air flow of 120 ml/min. Transmis-
sion electron microscopy (TEM) images were taken on
a JEOL JEM 2200-FS TEM. The 13C CP/MAS NMR
and 29Si MAS NMR spectra were recorded at 100.61 and
79.49 MHz, respectively, on a Bruker AVANCE-400 WB
dual channel spectrometer at room temperature with chem-
ical shifts relative to a tetramethylsilane standard. An over-
all 1000 free induction decays were accumulated. The
excitation pulse and recycle time for 13C CP/MAS NMR
spectra were 6 s and 2 s, respectively, and those for 29Si
MAS NMR spectra 6 s and 60 s.
3. RESULTS AND DISCUSSION
3.1. Structural Assessment
X-ray diffractograms (Fig. 2) show clear long-range struc-
tural ordering at low diffraction angles (2) of the m(MA)-
PMO materials as expected for template-based ordered
mesoporous materials with amorphous pore walls. An
intense (100) peak combined with the presence of two
minor second-order (110) and (200) peaks, are indicative
for a 2D-hexagonal (P6 mm) pore structure of the materi-
als. Increasing the loading of the functional organic bridge,
a decrease in structural ordering is observed, together
with a shift of d-spacing to lower values, pointing to a
decrease of the unit cell parameter a0 (Table I). Ulti-
mately, all ordering is lost for MA-PMO materials with
Fig. 2. X-ray diffraction patterns of MA5 (bottom), MA10, MA20,
MA30, MA40 and mMA10 (top).
more than 20 mol% of MA-precursor. This amount of pre-
cursor molecules, with relatively long and flexible organic
bridges, can no longer be properly arranged around the
micellating template.2(c) Compared to its MA counterpart,
a profound amelioration of the ordering is seen from the
XRD patterns of mMA10, which is most likely originat-
ing from a better template-precursor interaction due to the
extra hydrophobicity of the methyl groups.
Similar trends are observed through nitrogen
adsorption–desorption experiments (Fig. 3). MA5, 10,
20 and mMA10 all show type-IV isotherms with H1
hysteresis, typical for SBA15-like materials prepared with
P123 as a template. The high specific surface area (SBET
of MA5 and mMA10 drops significantly from 545 and
621 m2/g respectively, to 276 m2/g for MA20 (Table I).
Also the pore volume (Vp and pore diameter (dBJH are
affected in the same way, ranging from ∼0.9 mL/g and
6.8 nm for MA5 and mMA10 to 0.41 mL/g and 5.0 nm
for MA20, all with narrow pore size distribution (Fig. 4).
In agreement with XRD results, N2-isotherms of MA30
and MA40 suggest weak porosity due to the lack of
ordering, resulting in a low specific surface area and an
unreliable pore size distribution.
TEM-images (Fig. 5) show a clear visual confirmation
of the 2D ordered conformation of the PMO pores. Based
on these images, the estimated pore size is 7.0 nm and
5.0 nm for MA5 and MA20 respectively with a0 ∼9 nm
and 8.4 nm, which is in great accordance with XRD and
N2-sorption results. Very striking in the images are the
thicker pore walls, obtained as a result of a higher organic
content. Combined with the increased hydrophobicity, this
effect generally contributes to the increased hydrothermal
stability of PMOs compared to non-functional silicas.3(a)23
Fig. 3. N2 adsorption–desorption isotherms of MA40 (bottom), MA30,
MA20, MA10, MA5 and mMA10 (top).
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Fig. 4. Pore size distribution (BJH) of MA5 and mMA10 (∼7 nm),
MA10 and MA20 (∼5 nm) and MA30 and MA40.
3.2. Analysis of Functionalities Inside the Pore Walls
The DRIFT spectra of all samples (Fig. 6) show character-
istic C–H stretch vibrations at 2970, 2940 and 2890 cm−1,
originating from the propyl-group in the organic bridge.
For MA-PMOs, peaks at 1650 cm−1 and 1540 cm−1 are
assigned to Amide I (C O stretch) and Amide II (N–H
bend) vibrations, thus indicating the presence of a sec-
ondary amide in the PMO material. An increased relative
intensity of these peaks is observed for samples with a
higher mol% of the MA-precursor. Expected N–H stretch
vibrations possibly contribute to the broadened band from
residual adsorbed H2O at 3300 cm
−1. As mMA10 car-
ries tertiary amide functionalities in its pore walls, the
N–H bending vibration is absent. The C O stretch peak
remains present but is slightly red shifted to 1620 cm−1.
Almost complete removal of the P123 template by ace-
tone extraction is assumed as no significant C–H bending
vibrations are observed around 1350 cm−1. All samples
show a broad adsorption band between 1250–1000 cm−1
that indicates the formation of the framework’s silox-
ane (Si–O–Si) bonds. Deformation of this band may be
attribute to more forced binding angles of the lengthy
silsesquioxane moieties to form the curved pores wall.
Residual silanol (Si–OH) peaks show up at 950 cm−1,
indicating that the condensation of the precursors is not
complete.
The latter is also observed in the 29Si MAS NMR spec-
trum of MA20 in which both Qn (Qn = Si(OSi)n(OH)4−n
and Tn (Tn =RSi(OSi)n(OH)3−n signals are seen (Fig. 7).
The prominent Q4 peak at −110 ppm is only accompa-
nied by a Q3 shoulder at −100 ppm, thus indicating a
high degree of condensation of the siloxane network. A Q2
Fig. 5. TEM images of representative materials, MA5 (top) and MA20
(bottom). Inset: Zoom of pore size (dp) and unit cell parameter (a0).
signal of geminal silanols is completely absent. The pres-
ence of T3 and T2 signals (−63 and −52 ppm) confirms
the total incorporation of silsesquioxane into the pore wall,
again with the occurrence of a high condensation degree
and without cleavage of the Si–C bond under synthetic
conditions.
Figure 8 displays the 13C MAS NMR spectrum of
MA20. Signals at 9.6, 22.1 and 42.9 ppm arise from the
propylic moiety of the built in MA-functionality, being
the carbon shift of Si–CH2, Si–CH2–CH2 and CH2–NH
respectively. This last signal majorly overlaps the signal
of the methylene group in between the carbonyl groups,
which may be seen as a faint shoulder at 45.2 ppm. The
amide carbonyl signal is situated at 168 ppm. This result
confirms the unaltered fixation of MA functionalities in
the PMO structures.
The exact amount of (m)MA functionalities in the PMO
framework was quantitatively determined by elemental
analysis (CHNS) (Table I). Via the nitrogen content a
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Fig. 6. DRIFT spectra of MA5 (bottom), MA10, MA20, MA30, MA40
and mMA10 (top). Intensity of the signal in the 3750 cm−1–1450 cm−1
interval is enhanced for clarity.
maximum loading of 2.28 mmol/g was found for MA40.
At lower loading, MA5 and MA10, the entire amount
of used precursor was incorporated in the final materials.
However, for higher mole fractions a decrease of frame-
work functionality is found compared to the initial mix-
ture. This might be a result of the increased difficulty
to arrange a higher amount of long bis-silane molecules
around the template. Additional TGA experiments are con-
sistent with elemental analysis, as a greater weight loss
is observed with increasing functional loading (Fig. 9).
Moreover, TGA analysis shows that the investigated PMOs
are thermally stable up to approximately 270 C, after
which deterioration of the organic bridges occurs.
3.3. Ibuprofen Adsorption and CDR
Ever since the discovery of CDR systems, development
of new materials with different properties is ongoing.
Fig. 7. 29Si MAS NMR spectrum of MA20 as a representative material.
Fig. 8. 13C MAS NMR spectrum of MA20.
Such CDR systems should be able to deliver a fixed
concentration of a therapeutic agent over a considerable
times pan, preferably only in the targeted tissue, without
exceeding a toxicity threshold as encountered for burst
drug release. This concept can elegantly be tackled with
all types of porous materials, ranging from nanoporous
clays to polymer hydrogels, all allowing a vast intake
of drug molecules due to surface-adsorption. Next to
research on carriers for poorly water-soluble drugs, a
main focus is the optimization of the drug release pro-
file by means of the physical characteristics of the mate-
rials involved, such as porosity and particle size. More
recently, PMOs were proposed as promising CDR sys-
tems as a result of their large internal surface, chemical
stability, biocompatibility, non-toxicity and easy adapta-
tion of the structural parameters. The main advantage of
these organic–inorganic hybrid drug carriers is the possi-
bility to incorporate organic functionalities, which inter-
act with the drug molecule via non-covalent interactions.
The nature of these functionalities greatly influences the
Fig. 9. TGA profile of MA20 (bottom) and MA5 (top).
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adsorption and subsequent release of drugs as different
drug-matrix interactions may emerge. In this study, sec-
ondary and tertiary amides are proposed as functional
PMO-bridge to influence the adsorption and release rate
of ibuprofen. This hydrophobic anti-inflammatory drug is
used as a model drug as it has a small estimated dynamic
radius of 1 nm, thus avoiding physical pore size limita-
tions, which are suggested to initiate a delayed release for
MCM-type materials.12
Adsorption experiments (Table II) were only performed
on a selection of samples, which show good pore order-
ing. A high uptake of IBU, up to 0.303 mg/m2 for MA20,
was found via UV-VIS measurements of a hexane solution
before and after drug adsorption. With higher functional
loading, intrinsically more IBU is loaded in the PMO
pores, taking into account the varying internal surface
of the PMOs. This confirms the occurrence of increased
interactions, most likely H-bonding and hydrophobic–
hydrophobic interactions, between IBU and the PMO-
matrix. No noticeable variation in adsorption is observed
for the mMA-PMO with an extra methyl group. XRD of
IBU loaded samples show no peaks from crystalline IBU,
thus proving that IBU is adsorbed all over the pore walls as
an amorphous phase. This is verified by N2-sorption. After
adsorption, the surface area (SBET drops from 545 m
2/g
to 311 m2/g and from 276 m2/g to 168 m2/g for MA5
and MA20 respectively. Combined with a decrease of pore
size diameter (dBJH from 6.8 nm to 6.0 nm and 5.0 nm
to 4.3 nm, this indicates that IBU has partly filled the
mesopores.
CDR profiles of MA5 and M20 are depicted in
Figure 10. After a minor initial burst release of IBU
adsorbed on the external surface of the PMO parti-
cles, clear controlled release behaviour is shown for both
Fig. 10. IBU release profile of MA5 (top) and MA20 (bottom).
Fig. 11. Representation of electrostatic and H-bonding interactions of
IBU with a MAx (left) and mMAx (right) PMOs.
materials. Drug delivery as a function of time remains lin-
ear for approximately 8 h (0.083 m% IBUrel/h) for MA5,
which is a major improvement compared to SBA-15.18
A maximum of 93 m% IBU is released after 72 h in the
PBS at pH 7.4. Release of IBU loaded onto MA20 is
clearly slower with a linear profile up to 24 h (0.026 m%
IBUrel/h) as a result of the increased functional loading.
Due to this slow release rate, less (79 m%) of the adsorbed
IBU is released after 72 h. All this may be ascribed to
the fact that a higher MA-loading ensures more inter-
actions between IBU and the pore walls. Most likely,
a major contribution to these interactions is the electro-
static attraction between the negatively charged IBU at
pH 7.4 and the charged, amphoteric resonance structures
of the amide functionalities in the pore walls. Control-
ling the functional amide loading during synthesis, gives
PMO materials with specific and tunable CDR properties.
However, release experiments with IBU-loaded mMA10
(0.01 m% IBUrel/h) show no slower release rate because
of the added hydrophobicity of the tertiary amide. On the
contrary, a similar release profile as MA5 is found. Recent
calculations on the resonance structures of acetamide
show approximately 50% of amphoteric character for this
molecule.24 Here, this character induces electrostatic inter-
actions of IBU with both the MA as the mMA func-
tionality. For the MA-PMOs, however, N–H groups of
the secondary amide possibly remain available for extra
H-bonding interactions especially within the other, non-
charged amide resonance structure (Fig. 11). This effect
is absent in the tertiary amide of mMA10 (N-Me group),
resulting in a relatively faster IBU-release compared to
MA5. This pronounced difference between the two materi-
als might indicate H-bonding interactions, which are only
present for MAx-PMOs, also play a crucial role in the
fine-tuning of the IBU-retention in the PMO pores.
4. CONCLUSION
Two novel malonamide and N-methyl malonamide type
PMOs have been successfully synthesized via the co-
condensation of their respective precursors with TEOS in a
hydrothermal process. Structural integrity was maintained
up to a high functional loading of 1.34 mmol/g within
the pore walls. This allows adsorbing high quantities of
ibuprofen as a hydrophobic model drug inside the meso-
pores. The (m)MA PMOs are demonstrated to be efficient
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CDR systems for IBU in PBS (pH 7.4) with a controlled
linear release rate of up to 24 h as a result of reversible
host-drug interactions. Moreover, depending on the func-
tional loading, one is able to tune the release properties
for optimal IBU dosage.
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